Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer.

ABSTRACT:

Importance

A large proportion of patients with breast cancer concomitantly use adjuvant hormone therapy and cardiovascular therapy.

Objective

To examine the relative risk of discontinuing cardiovascular therapy during the periods before and after discontinuation of adjuvant hormone therapy.

Design, setting, and participants

This population-based cohort study included all women aged 40 to 74 years in Stockholm, Sweden, who were diagnosed with breast cancer and concomitantly using adjuvant hormone therapy and cardiovascular therapy. Patients were enrolled from July 1, 2005, to August 31, 2020, with a median follow-up of 7.2 years. Data were analyzed from November 3, 2021, to May 12, 2022.

Exposure

Discontinuation of adjuvant hormone therapy.

Main outcomes and

SUBMITTER: He W 

PROVIDER: S-EPMC10352860 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature